280. 巨大動静脈奇形（頚部顔面又は四肢病変） ［臨床試験数：17，薬物数：17（DrugBank：10），標的遺伝子数：8，標的パスウェイ数：106］
Searched query = "Huge arteriovenous malformation with cervicofacial or limb lesion", "Huge arteriovenous malformation", "Arteriovenous malformation"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900021901 | 2019-03-20 | 1 April 2019 | Efficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot Study | Efficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot Study | central nervous system arteriovenous malformations | Experimental group:Oral thalidomide;Control group:conservative or surgical treatment; | Xuanwu Hospital, Capital Medical University | Recruiting | Both | Experimental group:30;Control group:30; | Phase 0 | China | |||
| 2 | EUCTR2018-001359-11-FR | 22/02/2019 | 30 April 2019 | 0.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial | 0.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial - TOPICAL | Cutaneous microcystic lymphatic malformations (CMLM) in children and adults MedDRA version: 20.0 Level: LLT Classification code 10003229 Term: Arteriovenous malformations System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: Sirolimus 0,1% crème Pharmaceutical Form: Cream INN or Proposed INN: SIROLIMUS CAS Number: 53123-88-9 Concentration unit: % (W/W) percent weight/weight Concentration type: equal Concentration number: 0.1- Pharmaceutical form of the placebo: Cream Route of administration of the placebo: Cutaneous use | CHRU TOURS | Authorised | Female: yes Male: yes | 55 | Phase 2 | France | |||
| 3 | ChiCTR1800017616 | 2018-08-06 | 20 August 2018 | A randomized controlled trial for comparing the effect and outcomes with different embolic agent: Absolute ethanol, Onyx and n-BCA in the treatment of AVM | A randomized controlled trial for comparing the effect and outcomes with different embolic agent: Absolute ethanol, Onyx and n-BCA in the treatment of AVM | arteriovenous malformations | Ethanol group:Embolization with ethanol;Onyx group:Embolization with Onyx;n-BCA group:Embolization with n-BCA; | Shanghai 9th People's Hospital, Shanghai Jiaotong University School of Medicine | Recruiting | Both | Ethanol group:30;Onyx group:30;n-BCA group:30; | New Treatment Measure Clinical Study | China | |||
| 4 | ChiCTR1800015220 | 2018-03-14 | 30 April 2018 | Prospective evaluation of embolization with absolute alcohol in the treatment of arteriovenous malformations | Prospective evaluation of embolization with absolute alcohol in the treatment of arteriovenous malformations | arteriovenous malformations | Ethanol group:Embolization with absolute ethanol; | Shanghai 9th People's Hospital, Shanghai Jiaotong University School of Medicine | Recruiting | Both | Ethanol group:30; | New Treatment Measure Clinical Study | China | |||
| 5 | NCT02625389 | November 29, 2017 | 17 September 2018 | Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. | Safety and Efficacy of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. A Phase IV Study. | Congenital Hemangioma;Hemangioendothelioma;Angiosarcoma;Arteriovenous Malformation | Drug: Lipiodol® Ultra Fluid with surgical glues | Guerbet | Recruiting | 18 Years | N/A | All | 125 | Phase 4 | India | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | JPRN-UMIN000030522 | 2017/11/14 | 2 April 2019 | A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies | Intractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lymphatic anomaly, Kaposiform lymphangiomatosis), Gorham-Stout disease, Kaposiform hemangioendothelioma and Tuffted angioma with Kasabach-Merritt phenomenon, Nenous malformation, Arteriovenous malformation, Klippel-Trenaunay-Weber syndrome,Bluerubber bleb nevus syndrome, Complex-combined vascular malformations | Body surface area (BSA) >= 1.0m2: an initial dose of sirolimus (2mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day. BSA < 1.0m2: an initial dose of sirolimus (1mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day. | Gifu University | Recruiting | Not applicable | Not applicable | Male and Female | 50 | Not selected | Japan | ||
| 7 | NCT03306836 | September 2016 | 16 December 2017 | Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2 | Multi-center,Single Blind,Prospective Randomized Controlled Trial of Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation | Cerebral Aneurysm;Arteriovenous Malformations | Drug: Heparin Sodium | Beijing Tiantan Hospital | Tang-Du Hospital;Kunming Medical University;First Affiliated Hospital of Fujian Medical University;Nanjing PLA General Hospital;Fujian Medical University Union Hospital | Recruiting | N/A | 70 Years | All | 408 | N/A | China |
| 8 | NCT02314377 | June 2016 | 12 November 2018 | Bevacizumab Therapy for Brain Arteriovenous Malformation | Bevacizumab Therapy for Brain Arteriovenous Malformation | Brain Arteriovenous Malformation | Drug: Bevacizumab | University of California, San Francisco | Recruiting | 18 Years | 64 Years | All | 10 | Phase 1 | United States | |
| 9 | ChiCTR-IOR-16008047 | 2016-03-01 | 8 January 2018 | Early intervention of extracranial arteriovenous malformations with bleomycin: a prospective, multicenter, single-blind, randomized, controlled clinical trial | Early intervention of extracranial arteriovenous malformations with bleomycin: a prospective, multicenter, single-blind, randomized, controlled clinical trial | extracranial arteriovenous malformations | bleomycin group:Intralesional Bleomycin Injection;Control group:No medicine; | Shanghai 9th People's Hospital, Shanghai Jiaotong University School of Medicine | Recruiting | Both | bleomycin group:80;Control group:40; | Other | China | |||
| 10 | NCT03076099 | January 1, 2016 | 16 December 2017 | Dexmedetomidine on Post-operative Blood Pressure in Bain Arteriovenous Malformation Embolization | Effects of Dexmedetomidine on Post-operative Blood Pressure in Patients Undergoing Brain Arteriovenous Malformation Embolization | Anesthesia | Drug: Dexmedetomidine;Other: normal saline | Nan Jiang | Recruiting | 18 Years | 65 Years | All | 30 | N/A | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT02552459 | September 2015 | 24 October 2016 | Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery | Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery: A Randomized Controlled Study | Arteriovenous Malformation | Drug: Sufentanil;Drug: dexmedetomidine 1;Drug: dexmedetomidine 2;Drug: dexmedetomidine 3 | First Affiliated Hospital, Sun Yat-Sen University | Recruiting | 18 Years | 65 Years | Both | 120 | Phase 4 | China | |
| 12 | NCT02042326 | September 12, 2014 | 20 August 2018 | Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations | Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations | Arteriovenous Malformations | Drug: Sirolimus | Centre Hospitalier Universitaire, Amiens | Recruiting | 2 Years | N/A | All | 50 | Phase 2 | Belgium;France | |
| 13 | ChiCTR-OOB-15007258 | 2014-03-10 | 18 April 2017 | Early Intervention of Extracranial Arteriovenous Malformations with intralesional bleomycin injections: A Prospective Study | Early Intervention of Extracranial Arteriovenous Malformations with intralesional bleomycin injections: A Prospective Study | Arteriovenous Malformation | bleomycin group:intralesional adminstrated bleomycin ; | Shanghai 9th People's Hospital, Shanghai Jiaotong University School of Medicine | Recruiting | 2 | 60 | Both | bleomycin group:30; | Other | China | |
| 14 | NCT02496013 | January 2014 | 16 December 2017 | Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB | Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Diagnostic Performance of 68Ga-NEB in Healthy Volunteers and Patients With Hepatic Space-occupying Lesions and Suspicious Lymph Nodes Metastasis | Arteriovenous Malformation;Hemangioma;Neoplasms Lymph Nodes;Lymphedema | Drug: 68Ga-NEB | Peking Union Medical College Hospital | National Institute for Biomedical Imaging and Bioengineering (NIBIB) | Recruiting | 18 Years | N/A | All | 70 | Phase 1 | China |
| 15 | NCT00783523 | March 2008 | 19 February 2015 | Influence of MMP on Brain AVM Hemorrhage | Influence of Matrix Metalloproteinase on Brain Arteriovenous Malformation Hemorrhage | Arteriovenous Malformations;Cavernous Angiomas;Brain Aneurysms | Drug: Doxycycline or Placebo | University of California, San Francisco | Not recruiting | 13 Years | N/A | Both | 33 | Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT00389935 | October 2006 | 19 February 2015 | Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding | Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding | Arteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;Melena | Drug: Thalidomide | Northport Veterans Affairs Medical Center | Georgia Regents University;University of Massachusetts, Worcester | Not recruiting | 18 Years | N/A | Both | 14 | Phase 2 | United States |
| 17 | NCT00243893 | July 2004 | 19 February 2015 | Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms | Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms | Aneurysms;Arteriovenous Malformations | Drug: minocycline;Drug: doxycycline | University of California, San Francisco | National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 13 Years | 80 Years | Both | 26 | Phase 1 | United States |